Evidence map›Paper›PMID 41770279›Full record

ArticleCancer immunology, immunotherapy : CII2026

CAR T cells derived from a novel, high-affinity anti-CLL-1 monoclonal antibody exhibit a significant anti-AML effect.

Shuhei Kida, Makiko Suga, Yuta Yamaguchi, Shunya Ikeda, Yosuke Kogue, Ryuhei Kawamoto, Kumi Shibata, Kazuhito Tsutsumi, Hiraku Murakami, Emiko Mizuta and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shuhei Kida *Department of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan.
Makiko Suga *Department of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan.
Yuta YamaguchiDepartment of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan.
Shunya IkedaDepartment of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan.
Yosuke KogueDepartment of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan.
Ryuhei KawamotoDepartment of Clinical Laboratory and Biomedical Sciences, University of Osaka Graduate School of Medicine, Osaka, Japan.
Kumi ShibataDepartment of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan.
Kazuhito TsutsumiDepartment of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan.
Hiraku MurakamiDepartment of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan.
Emiko MizutaDepartment of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan.
Yo MizutaniDepartment of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan.
Naoki HosenDepartment of Hematology and Oncology, University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, Japan. hnaoki@bldon.med.osaka-u.ac.jp.

Funding

Japan Agency for Medical Research and Development 22cm0106381 and 25ama22134Japan Society for the Promotion of Science JPJSBP120237202 and JP20H03710
6 · The paper itself

Abstract

CAR T cells targeting CLL-1 have shown antileukemia efficacy in patients with acute myeloid leukemia (AML). However, CLL-1

Indexed as

Antibodies, MonoclonalImmunotherapy, AdoptiveLeukemia, Myeloid, AcuteReceptors, Chimeric AntigenT-LymphocytesAnimalsHumansMiceMice, Inbred NODMice, SCIDNucleophosminXenograft Model Antitumor AssaysAntibodies, MonoclonalNPM1 protein, humanNucleophosminReceptors, Chimeric AntigenAMLCAR T cellsCLL-1Menin inhibitorRevumenib

Identifiers

PMID41770279
PMCPMC12953792

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.